Curie.Bio

A pharmacist by training, Antoine Henninot Ph.D’s background has enabled him to collaborate effectively across many disciplines integral to drug discovery and development. During his time at Takeda, Antoine?established and led the peptide and bioconjugation team, overseeing multiple peptide drug discovery projects leveraging known hormones, or initiating campaigns for de novo ligands using various display technologies. Now, he’s lending his expertise to Curie.Bio founders to help them create best-in-class peptide-based therapies. Antoine shares more here. https://lnkd.in/ejGWG7if

?? Calling all Swiss #biotech founders! Curie.Bio is bringing its founder-focused model to?#Switzerland as a proud sponsor of?Bayer Co.Lab?Connect – Basel?alongside?Bayer,?Goodwin, Danforth Advisors, and Superlab Suisse. If you're building the next generation of therapeutics companies?in Switzerland?and want to break into the U.S. ecosystem, this is your opportunity. At Curie.Bio, we do more than invest—we help founders define, plan, and execute the drug discovery strategy that maximizes their chances of making impactful medicines.?Our 80+ drug hunters and biotech operators serve as an extension of your team, helping you hit critical milestones on your path to the clinic. With over?$1.2B raised,?500 vetted CROs, and a proven track record—like?Forward Therapeutics, Inc.?raising $50M for its Series A after just?18 months?and $8M—we know how to build serious therapeutics companies efficiently. If you're a Swiss biotech founder looking to?gain?access to world-class R&D resources and expert guidance, this program is designed for you. ?? Apply?here?by March 30.?https://lnkd.in/g5SDdvfS #FreeTheFounders?#SwissBiotech?

“I joined Curie.Bio because I believe our model is uniquely suited to helping new companies grow. There’s a level of expertise here that’s hard for any individual company to replicate or access, and that’s often the difference between a good outcome and a great one.”? ? Curie.Bio CXO Ankit Mahadevia has co-founded nine biotech companies, serving them in every role from advisor, Board member, investor, to CEO. He is well-equipped to help founders take their ideas and execution from good to great. https://lnkd.in/eAtNtXQ5

Today, we celebrate those pioneering groundbreaking therapies for those living with a #raredisease, the majority of which still need new treatment options. This includes Curie.Bio co-pilot Andy Garner. While much of Andy's experience at Blueprint Medicines focused on novel cancer treatments, he was able to leverage his expertise in kinase drug discovery to lead the discovery of fidrisertib, an ALK2 inhibitor that is currently advancing in the clinic as a potential treatment for Fibrodysplasia Ossificans Progressiva (FOP), a rare, debilitating genetic disorder characterized by the progressive formation of bone in soft tissues. #RareDiseaseDay

What does it really take to turn a bold idea into a transformative medicine? The journey is anything but straightforward—that’s why we’re excited to welcome Kelly Moynihan to Curie.Bio as a co-pilot to support the founders of our portfolio companies. Kelly has seen firsthand how early, strategic decisions—like target selection, indication prioritization, and development strategy—shape a company’s trajectory and long-term success. With hands-on experience in starting companies and advancing drugs from bench to clinic, she’s passionate about helping founders navigate the complexities of drug development. Read more about Kelly here: https://lnkd.in/gWE6PFXr

“It is a daunting task designing an efficacious, potent, and selective drug, with the desired pharmacokinetic profile, without causing toxicity, in a dosing regime acceptable for patients.” As a co-pilot at Curie.Bio, Chris Smith FRSC leverages his deep experience in designing multiple clinical-stage molecules to help founders create molecules with the right profile to make an impact for patients. Chris shares more about his passion for drug design on our website. https://lnkd.in/eUawThGt?

At Curie.Bio, we celebrate creative scientists and drug hunters who push the boundaries of what’s possible in medicine. On this International Day of Women & Girls in Science, we’re reminded of the powerful contributions women have made to drug discovery and development—most notably Marie Curie. Her pioneering research on radioactivity, including the discovery of polonium and radium, laid the foundation for radiation oncology and changed how we treat cancer today. Learn more about her incredible legacy via The Nobel Prize: https://lnkd.in/eSMB82Xd #WomenInScience

During his 20+ years as a Research & Early Development Scientist at Roche, Christian Klein has contributed to the development of over 30 clinical-stage drug candidates, including four approved therapies that continue to change patients’ lives daily. Now as a CXO at Curie.Bio, Christian works closely with our founders to translate their innovative ideas into actionable drug discovery programs. “I joined Curie.Bio because I believe in the power of collaboration. Throughout my career, I have learned that the best ideas often emerge from a diverse group of experts coming together, and Curie.Bio embodies that philosophy.” ? Learn more about Christian: https://lnkd.in/eYXrxC-w

Curie.Bio launched with an ambitious goal of being every founder's first phone call. After meeting thousands of incredible founders, we've fully deployed our first seed fund across 26 exciting companies, all pursuing blockbuster medicines. Today, we're pleased to announce our $340M Seed Fund 2, which will bolster our investment in the next wave of blockbuster medicines. Read more from STAT’s Allison DeAngelis, who sat down?with Zach Weinberg and?Alexis Borisy to discuss the evolution of Curie.Bio and what's ahead. https://lnkd.in/e96n_x3E

Co-founder and Operating Chairman Alexis Borisy created Curie.Bio to be what he, and many others, wished for when starting his first company. Alexis has founded 20 therapeutics & diagnostics companies throughout his career and brought multiple drugs to market. Alexis shares more about his copious experiences as a company creator leading to the founding of Curie.Bio in the latest episode of BiotechTV's? BioVenture VoiCes podcast.